BioGaia - Public Comps and Valuation Multiples

BioGaia Overview

About BioGaia

BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.

Founded

1990

HQ

Employees

225

Website

biogaia.se

Sectors

Nutraceuticals & Cosmeceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $158M

LTM EBITDA $46.8M

EV

$1.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

BioGaia Financials

As of August 2025, BioGaia reported last 12-month revenue of $158M and EBITDA of $46.8M.

In the same period, BioGaia generated $115M in LTM gross profit and $35.5M in net income.

See BioGaia valuation multiples based on analyst estimates

BioGaia P&L

In the most recent fiscal year, BioGaia reported revenue of $150M and EBITDA of $50.2M.

BioGaia expects next 12-month revenue of XXX and NTM EBITDA of XXX

See BioGaia valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$158M	XXX	$150M	XXX	XXX	XXX
Gross Profit	$115M	XXX	$109M	XXX	XXX	XXX
Gross Margin	73%	XXX	72%	XXX	XXX	XXX
EBITDA	$46.8M	XXX	$50.2M	XXX	XXX	XXX
EBITDA Margin	30%	XXX	33%	XXX	XXX	XXX
EBIT	$43.9M	XXX	$43.3M	XXX	XXX	XXX
EBIT Margin	28%	XXX	29%	XXX	XXX	XXX
Net Profit	$35.5M	XXX	$37.1M	XXX	XXX	XXX
Net Margin	23%	XXX	25%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for BioGaia including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $158M. EBITDA for the last twelve months was $46.8M. In the most recent fiscal year, BioGaia achieved $150M in revenue and $50.2M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$158M	Analyst estimates available to subscribers	$150M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$115M	Analyst estimates available to subscribers	$109M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	72.9% gross margin	Analyst estimates available to subscribers	72.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$46.8M	Analyst estimates available to subscribers	$50.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	29.7% EBITDA margin	Analyst estimates available to subscribers	33.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$43.9M	Analyst estimates available to subscribers	$43.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	27.8% EBIT margin	Analyst estimates available to subscribers	28.8% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$35.5M	Analyst estimates available to subscribers	$37.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	22.5% net profit margin	Analyst estimates available to subscribers	24.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for BioGaia

This financial data table provides comprehensive performance metrics for BioGaia, a company based in Sweden. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

BioGaia generated $158M in revenue over the last twelve months.
The company achieved $46.8M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $115M.
Net income over the last twelve months reached $35.5M.

Fiscal Year Performance

In the most recent fiscal year, BioGaia reported $150M in total revenue.
Fiscal year EBITDA was $50.2M.
The company maintained a gross profit margin of 72.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was 33.4%.
Net profit margin reached 24.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for BioGaia. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

BioGaia Stock Performance

BioGaia has current market cap of SEK 10.9B (or $1.2B), and EV of SEK 10.3B (or $1.1B).

Market Cap Evolution

BioGaia Stock Data

As of September 30, 2025, BioGaia's stock price is SEK 108 (or $11).

See BioGaia trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.1B	$1.2B	XXX	XXX	XXX	XXX	$0.36

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

BioGaia Valuation Multiples

BioGaia's trades at 7.3x EV/Revenue multiple, and 21.7x EV/EBITDA.

See valuation multiples for BioGaia and 15K+ public comps

BioGaia Financial Valuation Multiples

As of September 30, 2025, BioGaia has market cap of $1.2B and EV of $1.1B.

Equity research analysts estimate BioGaia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

BioGaia has a P/E ratio of 32.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.2B	XXX	$1.2B	XXX	XXX	XXX
EV (current)	$1.1B	XXX	$1.1B	XXX	XXX	XXX
EV/Revenue	6.9x	XXX	7.3x	XXX	XXX	XXX
EV/EBITDA	23.3x	XXX	21.7x	XXX	XXX	XXX
EV/EBIT	24.8x	XXX	25.2x	XXX	XXX	XXX
EV/Gross Profit	9.5x	XXX	n/a	XXX	XXX	XXX
P/E	32.6x	XXX	31.2x	XXX	XXX	XXX
EV/FCF	31.3x	XXX	28.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get BioGaia Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

BioGaia Margins & Growth Rates

BioGaia's last 12 month revenue growth is 9%

BioGaia's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.

BioGaia's rule of 40 is 47% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

BioGaia's rule of X is 52% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for BioGaia and other 15K+ public comps

BioGaia Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	9%	XXX	8%	XXX	XXX	XXX
EBITDA Margin	30%	XXX	33%	XXX	XXX	XXX
EBITDA Growth	19%	XXX	-7%	XXX	XXX	XXX
Rule of 40	47%	XXX	42%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	52%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.7M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	30%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	11%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	44%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial